Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.

Autor: Filippatos, Gerasimos1 (AUTHOR) gfilippatos@gmail.com, Butler, Javed2,3 (AUTHOR) butlzih@gmail.com, Farmakis, Dimitrios4 (AUTHOR) dimitrios_farmakis@yahoo.com, Zannad, Faiez5 (AUTHOR) f.zannad@chru-nancy.fr, Ofstad, Anne Pernille6,7 (AUTHOR) annepernille@hotmail.com, Ferreira, João Pedro5,8 (AUTHOR) jp7ferreira@hotmail.com, Green, Jennifer B.9 (AUTHOR) jennifer.green@duke.edu, Rosenstock, Julio10 (AUTHOR) juliorosenstock@dallasdiabetes.com, Schnaidt, Sven11 (AUTHOR) sven_yannik.schnaidt@boehringer-ingelheim.com, Brueckmann, Martina12,13 (AUTHOR) martina.brueckmann@boehringer-ingelheim.com, Pocock, Stuart J.14 (AUTHOR) stuart.pocock@lshtm.ac.uk, Packer, Milton15,16 (AUTHOR) milton.packer@baylorhealth.edu, Anker, Stefan D.17,18 (AUTHOR) s.anker@cachexia.de, EMPEROR-Preserved Trial Committees and Investigators (CORPORATE AUTHOR)
Zdroj: Circulation. 8/30/2022, Vol. 146 Issue 9, p676-686. 11p.
Databáze: Academic Search Ultimate